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1170–7.Comment on the Use of Vignettes and the EQ-5D to Value Disease-
Specific Health StatesTo the Editor – We are concerned about the techniques used in an
ttempt to elicit utility weights reported in the recent article by Gal-
nte et al. titled “Estimation and comparison of EQ-5D health states’
tility weights for pneumococcal and human papillomavirus dsease
n Argentina, Chile, and the United Kingdom” in the July/August
5, Suppl. 1) 2011 issue of Value in Health titled “3rd Special Issue:
Pharmacoeconomics and Outcomes Research in Asia” [1]. That study
aimed to estimate and compare the utility weights for health states
associated with pneumococcal and human papilloma virus for Ar-
gentina, Chile, and the United Kingdom.
The investigators developed eight vignettes for pneumococcal
health states and four vignettes for human papillomavirus states.
After the vignettes were described to convenience samples, subjects
completed the EuroQol five-dimensional (EQ-5D) questionnaire for
each state described. Their responses were collated as five-digit
numbers given for each EQ-5D questionnaire health state and paired
with their available corresponding utility weights in each country.
The major shortcoming with this approach is that the respond-
ers “rate” the health state description on the EQ-5D questionnaire.
If the health state was described by using the domains of mobility,
personal care, usual activities, pain, and anxiety/depression (i.e.,
the EQ-5D questionnaire domains), then the respondents merely
need to map the description to the EQ-5D questionnaire levels.
The health states that are well described would result in all re-
spondents scoring identical levels for each domain. For example, a
health state could be described as “no problems walking around,
some problems with washing or dressing, unable to perform usual
activities, moderate pain or distress, and extreme anxiety” and all
respondents would score this as 12323 on the EQ-5D question-
naire. For health state descriptions that match the domains of an
instrument (including those developed from an instrument), there
is no need to have respondents score the description. If the health
state descriptions do not include the domains used in the EQ-5D
questionnaire, however, then the respondents will struggle map-
ping the descriptions to the instrument; in this circumstance, the
instrument is not appropriate to use for the health state being
described because it lacks the necessary constructs for validity.
Unfortunately, Galante et al. [1] do not describe the development
of the vignettes or the translation or the linguistic validation of the
vignettes, given that the study was carried out in three countries.
Rather than undertaking a poorly designed and flawed experi-
ment, there were at least two alternative methods open to the au-
thors [2]. One approach is scenario based using vignettes developed
with patients and clinical experts. The vignettes, in turn, can be val-the standard gamble or time trade-off where the value obtained for
each vignette may differ with the desirability or the preference of
each subject toward the given scenario [3]. The second more practical
method available to the authors would have been, because all the
three countries had already valued EQ-5D questionnaire utility
weights, to obtain a sample of “patients” with different degrees of
disease severity of pneumococcal and human papillomavirus in each
country and to administer the EQ-5D questionnaire to the patients to
describe the health state they were experiencing. Then the appropri-
ate utility scoring algorithm for the respective country could be ap-
plied [4].
We cannot emphasize enough the need to use sensible and
scientifically valid methods rather than repeating approaches
such as those described by Galante et al.
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